APA (7th ed.) Citation

R, A., P, A., S, B., E, E., MO, O., AB, A., . . . S, O. (2026). Nivolumab and ipilimumab combination therapy for melanoma efficacy, safety and clinical integration in metastatic and adjuvant settings. Discover oncology, 17(1), . https://doi.org/10.1007/s12672-026-05202-x

Chicago Style (17th ed.) Citation

R, Afuh, et al. "Nivolumab and Ipilimumab Combination Therapy for Melanoma Efficacy, Safety and Clinical Integration in Metastatic and Adjuvant Settings." Discover Oncology 17, no. 1 (2026). https://doi.org/10.1007/s12672-026-05202-x.

MLA (9th ed.) Citation

R, Afuh, et al. "Nivolumab and Ipilimumab Combination Therapy for Melanoma Efficacy, Safety and Clinical Integration in Metastatic and Adjuvant Settings." Discover Oncology, vol. 17, no. 1, 2026, https://doi.org/10.1007/s12672-026-05202-x.